CONMED Corporation (NYSE:CNMD – Get Free Report) has been assigned an average recommendation of “Reduce” from the eight brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.80.
Several analysts have weighed in on CNMD shares. Wells Fargo & Company set a $39.00 price target on shares of CONMED in a research note on Monday, July 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Wall Street Zen raised CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Bank of America restated an “underperform” rating and set a $40.00 target price on shares of CONMED in a report on Monday, June 29th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of CONMED in a report on Thursday, June 4th.
Check Out Our Latest Analysis on CONMED
Institutional Trading of CONMED
CONMED Trading Up 1.6%
CNMD stock opened at $44.20 on Friday. The company has a market capitalization of $1.33 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 3.22 and a beta of 0.93. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. CONMED has a one year low of $31.44 and a one year high of $56.63. The company’s 50 day moving average price is $36.76 and its two-hundred day moving average price is $38.40.
CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The company had revenue of $317.05 million during the quarter, compared to analysts’ expectations of $310.64 million. During the same quarter in the prior year, the company earned $0.95 EPS. The firm’s revenue was down 1.3% on a year-over-year basis. As a group, analysts predict that CONMED will post 4.38 earnings per share for the current fiscal year.
About CONMED
CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.
CONMED operates two principal segments: Orthopedics, and Visualization & Energy.
See Also
- Five stocks we like better than CONMED
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
